The dosing scheme is stepwise and is individualized for each woman [see Clinical Studies].
Discourage intercourse when the risk for OHSS is increased [see WARNINGS AND PRECAUTIONS].
The recommended dosing scheme for patients undergoing IVF  follows a stepwise approach and is individualized for each woman. The recommended initial dose of BRAVELLE®  for women who have received a GnRH agonist for pituitary suppression is 225 International Units. BRAVELLE®  may be administered together with MENOPUR® (menotropins for injection, USP), and the total initial dose when the products are combined should not exceed 225 International Units (150 International Units of BRAVELLE®  and 75 International Units of MENOPUR® or 75 International Units of BRAVELLE® and 150 International Units of MENOPUR®).
